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Abstract
The aim of this study was the identiﬁcation of subgroups of patients at higher risk of nonadherence to adjuvant
hormone therapy for breast cancer. Using recursive partitioning and amalgamation (RECPAM) analysis, the
highest risk was observed in the group of unmarried, employed women, or housewives. This result might be
functional in designing tailored intervention studies aimed at improvement of adherence.
Background: Adherence to adjuvant endocrine therapy (HT) is suboptimal among breast cancer patients. A high rate
of nonadherence might explain differences in survival between clinical trial and clinical practice. Tailored interventions
aimed at improving adherence can only be implemented if subgroups of patients at higher risk of poor adherence are
identiﬁed. Because no data are available for Italy, we undertook a large survey on adherence among women taking
adjuvant HT for breast cancer. Patients and Methods: Patients were recruited from 10 cancer clinics in central Italy.
All patients taking HT for at least 1 year were invited, during one of their follow-up visit, to ﬁll a conﬁdential ques-
tionnaire. The association of sociodemographic and clinical characteristics of participants with adherence was
assessed using logistic regression. The RECPAM method was used to evaluate interactions among variables and to
identify subgroups of patients at different risk of nonadherence. Results: A total of 939 patients joined the study and
18.6% of them were classiﬁed as nonadherers. Among possible predictors, only age, working status, and switching
from tamoxifen to an aromatase inhibitor were predictive of nonadherence in multivariate analysis. RECPAM analysis
led to the identiﬁcation of 4 classes of patients with a different likelihood of nonadherence to therapy, the lowest being
observed in retired women with a low level of education, the highest in the group of unmarried, employed women, or
housewives. Conclusion: The identiﬁcation of these subgroups of “real life” patients with a high prevalence of
nonadherers might be functional in designing intervention studies aimed at improving adherence.
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Nonadherence with drug therapy, in chronic conditions such as
hypertension, diabetes mellitus, and postmenopausal osteoporosis
has long been recognized as a major issue in health care, especially
when self-administration of oral medicines is required.1 Obviously,
a less than optimal adherence to therapy might lead to worsening of
the disease and this could be erroneously attributed by the clinician
to the lack of activity of the drug.2
The availability of oral drugs for the treatment of cancer has
increased in recent years, and it is estimated that approximately 25%
of all anticancer agents currently in development will be available as
oral formulations.3 Largely, this phenomenon follows patient pref-
erences, dictated by convenience.4,5 Indeed, the avoidance of
frequent trips to health care facilities, insertion of central venous
lines, discomfort from infusion, and risks of associated adverse
events, are not trivial advantages of oral cytotoxic therapies over
traditional, intravenously administered ones. The downside to this
is that health care professionals no longer directly monitor treatment
administration, thus justifying the increased concern among on-
cologists about adherence of patients to oral treatment.6
The issue of adherence is especially important for the adjuvant
endocrine therapy (HT) of early breast cancer, that relies on oral
drugs administered for 5 or more years.7 In fact, although perceived
as strongly motivated by the life-threatening nature of their disease,
women taking oral HT were found to be nonadherent to therapy in
15% to 50% of the cases, and more often in real life than in the
clinical trial setting.8 Moreover, low adherence to HT has been
associated with shorter survival.9 Because the rate of adherence
appears to decrease with increasing duration of therapy,10 this
problem might become even more serious considering recent ﬁnd-
ings of further reduction of mortality from breast cancer with longer
HT treatment.11
Interventions aimed at promoting adherence have been tested in
several studies, but a recent review concluded that none of them
were effective.12 One of the reasons for these disappointing results is
that interventions were quite generic and not adapted to the need of
the patient.13 It is, therefore, necessary to identify subgroups of
patients with a higher risk of poor adherence to put tailored in-
terventions in place.1 It is well known that side effects of HT are
main determinants of suboptimal adherence to HT. However, it has
been found that the latter is a multidetermined behavior, being
inﬂuenced by socioeconomic- and health care system-related factors
among others,6,14 it is likely that the characteristics of these patients
differ from country to country. Because no data of this kind are
available for Italy, we carried out a large survey on adherence among
women taking adjuvant HT for breast cancer, and the results are
reported herein.
Patients and Methods
Patients
Participants were recruited from 10 cancer clinics mainly located
in central Italy and treating at least 100 breast cancer patients per
year. Women taking adjuvant HT for breast cancer were identiﬁed
among patients attending regular follow-up visits. All patients
treated for at least 1 year were approached by their oncologists
during one of the routine appointments and invited to join the
survey. Patients were asked to anonymously complete a structured- Clinical Breast Cancer April 2015questionnaire and to drop it into a ballot box. Because it was not
possible for the physician to verify if the questionnaire was
completely ﬁlled, the number of respondents might be different for
each question. The questionnaire included items regarding socio-
demographic characteristics (age, marital status, number of children,
area of residence, level of education, type of work) and medical
history (year and type of surgery, radiation and chemotherapy,
details on duration and type of hormone therapy).
To verify adherence, patients had to indicate how often they did
not take the tablets during the past month and if the drug was taken
at the same time each day. Other questions were included to assess
reasons for not taking the medications (intentionally or uninten-
tionally), beliefs about the effectiveness of the hormone therapy,
number of medications taken each day, presence of a depressed
mood. All the questions were posed in a nonjudgmental form.
Patients who reported to have not regularly taken their medication
at least 4 times during the past month were retained as nonadherers.
The study was approved by the independent Ethics Committees
of participating institutions and written informed consent was
obtained from each participant. The consent procedure was
approved by the same Ethics Committees.
Statistical Analysis
Prevalence of nonadherence to therapy according to patient
characteristics was determined and the association with each
covariate was expressed in terms of unadjusted odds ratio (OR) with
the 95% conﬁdence interval (CI). A multiple logistic regression was
used to identify characteristics independently associated with non-
adherence to therapy. Covariates resulting as statistically signiﬁcant
in univariate analysis were introduced in the ﬁnal model. The
recursive partitioning and amalgamation (RECPAM) tree-based
methods was used to evaluate interactions among the different
variables and to identify distinct and homogeneous subgroups of
patients with different risk of nonadherence.15 Patient age served as
the global predictor (ie, its effect was considered to be equally
important in all subgroups indentiﬁed using the method). A further
multivariate logistic regression analysis with the RECPAM classes
forced-in the model was run, testing all other characteristics not
entering the tree. A P value < .05 was considered for statistical
signiﬁcance. All analyses were performed using SAS release 9.1 (SAS
Institute, Cary, NC).
Results
A total of 939 patients joined the study. The overall participation
rate was > 90%. Sociodemographic characteristics of the patients
are detailed in Table 1. Median age was 62 years (interquartile
range, 52-71 years) and most patients were postmenopausal (70%).
More than 81% (N ¼ 764) of participants were married and 378
(40%) had a secondary or higher education. With respect to
working status, 348 (37%) were retired, 366 (39%) were house-
wives, and 200 (21%) employed.
Clinical characteristics of participants are reported in Table 2.
Breast-conserving surgery was more than twice as common as
mastectomy, and approximately half of the patients had received
previous adjuvant chemotherapy. Most participants were taking
aromatase inhibitors (71%), and among them only 11% had
switched from tamoxifen.
Table 1 Sociodemographic Characteristics of Participants
Variable n (%)
Age Category, Years
45 89 (9.5)
46-60 325 (34.6)
61-70 252 (26.8)
>70 260 (27.7)
Missing 13 (1.4)
Region of Residence
Abruzzi 307 (32.7)
Lazio 557 (59.3)
Umbria 43 (4.6)
Others 32 (3.4)
Marital Status
Married 764 (81.4)
Unmarried/divorced 160 (17.0)
Missing 15 (1.6)
Number of Offspring
0 113 (12.0)
1 805 (85.7)
Missing 21 (2.3)
Level of Education
No education/elementary 295 (31.4)
Middle school 216 (23.0)
High school 378 (40.3)
Missing 50 (5.3)
Work Status
Retired 348 (37.1)
Housewife 366 (38.9)
Employed 200 (21.3)
Missing 25 (2.7)
Table 2 Clinical Characteristics of Participants
Variable n (%)
Type of Surgery
Quadrantectomy/segmentectomy 616 (65.6)
Mastectomy 253 (26.9)
Missing 70 (7.5)
Time From Surgery, Years
2 129 (13.7)
3-4 364 (38.7)
5 434 (46.3)
Missing 12 (1.3)
Adjuvant Radiotherapy
Yes 686 (73.1)
No 236 (25.1)
Missing 17 (1.8)
Adjuvant Chemotherapy
Yes 451 (48.0)
No 448 (47.7)
Missing 40 (4.3)
Menopausal Status at the Start
of Endocrine Therapy
Premenopausal 276 (29.4)
Postmenopausal 655 (69.7)
Missing 8 (0.9)
Time of Adjuvant Endocrine
Therapy, Months
18 86 (9.1)
19-36 287 (30.6)
>36 551 (58.7)
Missing 15 (1.6)
Current Endocrine Therapy
Tamoxifen 239 (25.5)
Aromatase inhibitors 668 (71.1)
Missing 32 (3.4)
Switch From Tamoxifen to
Aromatase Inhibitors
Yes 105 (11.2)
No 806 (85.9)
Missing 28 (2.9)
Nicola Tinari et alOverall, our study population appeared to be highly motivated in
taking the prescribed drug, as 729 (77.6 %) patients were conﬁdent
that therapy would be effective in curing cancer. According to the
operative deﬁnition of adherence adopted in the study, 18.5% of
patients were considered to be nonadherers. Basically, nonadherence
was largely unintentional, because 94.6% of nonadherers declared
to forget to take the tablet or to reﬁll the prescription. Only 9
patients reported to have intentionally discontinued treatment
before the completion of 5 years of therapy.
Sociodemographic and clinical characteristics and adherence data
were similar among patients from different institutions. Potential
predictors of nonadherence identiﬁed in univariate and multivariate
analysis are reported in Table 3. Only age, working status, and
switching from tamoxifen to an aromatase inhibitor were signiﬁcant
predictors of nonadherence in multivariate analysis. Older women
showed the highest adherence rate (88.8%). In relation to this
reference class, the risk of nonadherence among other age classes was
greater. In particular, patients  45 years of age (OR, 2.56; 95%
CI, 1.03-6.34; P ¼ .0424) and those between 61 and 70 years of
age (OR, 1.93; 95% CI, 1.09-3.41; P ¼ .0233) had the greatest
odds of being nonadherent. According to the working status, retiredpatients showed the lowest percentage of nonadherers (11.8%), and
the greatest odds of nonadherence was observed for housewives
(OR, 1.92; 95% CI, 1.17-3.15; P ¼ .0101). Finally, the risk of
nonadherence was greater among patients who switched from
tamoxifen to aromatase inhibitors. Notably, no association with
adherence was observed for some treatment-related factors, such as
type of surgery, time from surgery, previous adjuvant chemo-
therapy, duration of hormone therapy, and the number of drugs
taken.
Recursive partitioning and amalgamation analysis with age as the
global predictor led to the identiﬁcation of 4 classes of patients with
a different likelihood of nonadherence (Figure 1). The most
important variable for determining the risk of nonadherence was
represented by working status, with the lowest prevalence (8.7%) inClinical Breast Cancer April 2015 - e133
Table 3 Univariate and Multivariate Analysis of Factors Predicting Nonadherence to Endocrine Therapy
Variable
Adherers,
n (%)
Nonadherers,
n (%)
Univariate LR Multivariate LR
OR 95% CI P OR 95% CI P
Age, Years
45 62 (71.3) 25 (28.7) 3.2 1.74-5.87 .0002 2.56 1.03-6.34 .0424
46-60 254 (79.4) 66 (20.6) 2.06 1.28-3.32 .003 1.52 0.76-3.04 .2355
61-70 198 (80.2) 49 (19.8) 1.96 1.19-3.24 .0085 1.93 1.09-3.41 .0233
>70 222 (88.8) 28 (11.2) 1 1
Marital Status
Married 619 (82.7) 129 (17.3) 1 1
Unmarried/divorced 115 (74.7) 39 (25.3) 1.63 1.08-2.45 .0199 1.42 0.82-2.34 .1693
Number of Offspring
0 84 (74.3) 29 (25.7) 1.64 1.04-2.60 .0348 1.34 0.78-2.32 .2926
1 647 (82.6) 136 (17.4) 1 1
Level of Education
No education/elementary 248 (86.7) 38 (13.3) 1 1
Middle school 170 (80.2) 42 (19.8) 1.61 1.00-2.61 .0512 1.23 0.71-2.14 .4581
High school 289 (77.9) 82 (22.1) 1.85 1.22-2.82 .0041 1.37 0.82-2.29 .2278
Work Status
Retired 300 (88.2) 40 (11.8) 1 1
Housewife 275 (77.3) 81 (22.7) 2.21 1.46-3.34 .0002 1.92 1.17-3.15 .0102
Employed 151 (77.0) 45 (23.0) 2.24 1.4-3.57 .0008 1.58 0.85-2.95 .1462
Type of Surgery
Quad/segmentectomy 494 (81.2) 114 (18.7) 1.02 0.69-1.49 0.9376
Mastectomy 198 (81.4) 45 (18.6) 1
Time From Surgery, Years
2 106 (84.1) 20 (15.9) 1
3-4 282 (78.5) 77 (21.5) 1.45 0.84-2.48 .1799
5 350 (83.1) 71 (16.9) 1.08 0.63-1.85 .7932
Adjuvant Radiotherapy
Yes 539 (80. 5) 131 (19.5) 1.24 0.83-1.84 .2864
No 194 (83.6) 38 (16.4) 1
Adjuvant Chemotherapy
Yes 353 (80.0) 88 (20.0) 1.20 0.85-1.84 .2864
No 365 (82.77) 76 (17.23) 1
Menopausal Status at the
Start of Endocrine Therapy
Premenopausal 212 (77.3) 62 (22.7) 1.45 1.02-2.05 .0395 0.76 0.44-1.31 .3213
Postmenopausal 529 (83.1) 107 (16.9) 1
Adjuvant Endocrine
Therapy, Months
18 70 (82.3) 15 (17.7) 1
19-36 227 (80.1) 54 (19.9) 1.11 0.59-2.09 .7458
>36 438 (81. 6) 99 (18.4) 1.05 0.58-1.92 .8614
Current Endocrine Therapy
Tamoxifen 184 (77.3) 54 (22.7) 1.44 1.00-2.07 .0513
Aromatase inhibitors 544 (83.0) 111 (17.0) 1
Switch From Tamoxifen
to Aromatase Inhibitors
Yes 75 (71.4) 30 (28.6) 1.95 1.23-3.09 .047 1.80 1.08-3.01 .0248
No 657 (83.0) 135 (17.0) 1
Abbreviations: LR ¼ logistic regression; Quad ¼quadrantectomy.
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Table 4 Logistic Regression Model With Forced-In
RECPAM Classes
Variable OR (95% CI) P
RECPAM Class
1 4.79 (2.43-9.45) <.0001
2 2.68 (1.52-4.72) .0007
3 2.58 (1.26-5.92) .0097
4 1
Switch Therapy
Yes 1.78 (1.08-2.92) .0240
No 1
Abbreviation: RECPAM ¼ recursive partitioning and amalgamation.
Nicola Tinari et alretired women with a low level of education (class 4). This subgroup
served as the reference category (OR, 1) for the estimation of OR
for other classes. On the opposite side of the regression tree, patients
employed or housewives and unmarried represented the subgroup
with the highest prevalence of nonadherence (33.7%). The esti-
mated risk of nonadherence for this last subgroup was 4.5 times
greater than that of the reference group (OR, 4.61; 95% CI,
2.36-9.28). The other 2 classes of patients, namely those retired
with a secondary or higher education (class 3) and married
employed or housewives (class 2), displayed a very similar prevalence
of nonadherers (18.5% vs. 20.3%) with a risk of approximately 2.4
times greater than the reference group. A ﬁnal logistic regressionFigure 1 Recursive Partitioning and Amalgamation (RECPAM) Analy
as Outcome After Multivariate Logistic Regression in Which
Between Branches, and Condition Sending Patients to Lef
Prevalence of Nonadherent Patients Was the Reference Ca
Squares Indicate RECPAM Classes. Numbers Inside Circle
(Italic) to Therapymodel with RECPAM classes forced-in showed that switching to an
aromatase inhibitor was retained in the ﬁnal model as a globally
predictive variable associated with an increased likelihood of non-
adherence to therapy (OR, 1.78; 95% CI, 1.08-2.92; P ¼ .024;
Table 4).
Discussion
A less than optimal adherence to the prescribed medications is a
well-known medical issue, especially for chronic diseases requiring
treatments lasting several months or years. The increased availability
of anticancer drugs in oral formulation undoubtedly results in
greater patient convenience. However, taking oral drugs out of the
direct control of the medical staff has rendered nonadherence to
therapy as challenging in oncology as in other diseases.6 In this
regard, a major area of concern is represented by the adjuvant
endocrine treatment of breast cancer.
The results of our survey show that the declared nonadherence of
Italian women to HT is in the range of 15% to 50%, as reported in
previous studies.16 The large variability of adherence rate is widely
dependent on the different assessment methods.17 Although no
method can be considered optimal,1 self-reporting through ques-
tionnaire might overestimate adherence, being prone to a number of
biases such as the response bias and the self-presentation bias.18
These biases consist of a tendency to respond in a certain way to
a questionnaire in an attempt to please the interviewer (response
bias)19 or inﬂuence the way the interviewer perceives the inter-
viewed (self-presentation bias).20 Analysis of prescription reﬁll issis. Tree Growing Algorithm Modeled OR for Nonadherence
Age Was a Global Variable. Splitting Variables (Red) Are Shown
t or Right Sibling Is on Relative Branch. Class 5 With Lowest
tegory (OR [ 1). Circles Indicate Subgroups of Patients.
s and Squares Represent Number of Patients Adherent or Not
Clinical Breast Cancer April 2015 - e135
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to therapy, because it avoids this kind of patient manipulation.21,22
This method provided more consistent results, with a rate of overall
adherence of approximately 50%.8,9,23 In our study, it was not
possible to use prescription reﬁlls, because not all the participating
institutions could gain access to the pharmacy records. However, we
believe that both types of bias were mitigated in our study by the
conﬁdential nature of the questionnaire. A possible limitation of our
approach is the limited number of items included in the ques-
tionnaire. However, this was the result of a trade-off between
simplicity and comprehensiveness, so as to not discourage patient
participation in the study.
Another important determinant of variation in the rates of
adherence is represented by its deﬁnition. In most studies, non-
adherers were considered those patients taking < 80% of the pre-
scribed dose,23,24 and this cutoff has been found to be associated
with survival.9,25 We adopted a more relaxed deﬁnition, with
nonadherers considered those who declared not taking their tablets
for at least 4 times during the past month. Whether this extent of
nonadherence affects survival is not known at the moment.
Notably, other studies have used a very similar deﬁnition and the
same method of measurement.26,27 The rate of adherence reported
by Oberguggenberger et al27 is comparable to ours, whereas Atkins
and Fallowﬁeld26 reported a rate of 50%, which probably depended
on an even less stringent deﬁnition of adherence.
We found an extremely low discontinuation rate probably linked
to the setting we chose to conduct the survey. Indeed, it is very
likely that patients who have discontinued the treatment are also
those no more attending the scheduled follow-up visits. It follows
that our study might be affected by such a selection bias. This
consideration might also explain why, apparently, in our study the
rate of adherence did not decline with the time of HT, which has
been consistently observed by others in cancer and chronic
diseases.1,23
Multiple regression analysis identiﬁed several predictors of poor
adherence to HT. Among these, age is of major importance. It
would be expected that older people are more likely to be non-
adherent for a number of reasons, such as cognitive impairment,
problems in swallowing tablets, handling them or distinguishing
their colors, comorbidities, and a higher number of prescribed
medications.28,29 However, in our study adherence increased with
age. Women younger than 45 years had the highest risk of being
nonadherent followed by those in the age group of 61 to 70 years.
This ﬁnding is in agreement with previous studies,25,26,30 although
in others adherence was lower at the extremes of age.10,23,24 It is
now widely recognized that young cancer patients must be regarded
as a vulnerable group of patients, because of greater affective distress
and greater difﬁculties in coping with their disease,31,32 mainly due
to the perceived loss of youth, femininity, and fertility associated
with side effects of HT.33 Other authors suggest that the higher rate
of adherence among older patients might reﬂect a survivor bias,
because adherent patients might survive longer.6
We found that the type of HT has no relation with adherence.
Data from clinical trials indicate that, compared with tamoxifen,
adherence rates are higher for anastrozole,34 similar for letrozole,35
and slightly lower for exemestane.36 In agreement with other
studies,37 we found that patients who have switched from tamoxifen- Clinical Breast Cancer April 2015to an aromatase inhibitor have a higher risk of nonadherence. This
appears to be in contrast with the current belief that there is overall
better tolerability of at least some type of aromatase inhibitors.38
However, this concept has been recently challenged and attrib-
uted to a partial assessment, in clinical trials, of the side effects of
aromatase inhibitors.39 It should be noted that in our study, side
effects of drugs has no relation with adherence, although they were
only indirectly assessed.
Another factor associated with an increased risk of nonadherence
is represented by the working status, with nonretired patients being
at higher risk of nonadherence. In a recently published prospective
study, employment status was found to signiﬁcantly affect adher-
ence to HT in postmenopausal women with early breast cancer,
with nonadherers being prevalent among nonretired patients.40
Interests and commitments related to an active working status
might represent barriers to effective self-care and regular drug
assumption.41
Medication costs, consistently associated with poor adherence to
treatment in countries requiring health insurance coverage,42 were
not evaluated in our study because in Italy health care is provided by
the National Health Service and oral drugs for the treatment of
cancer are subsidized, with no copayment required.
Finally, although the number of patients enrolled in the survey
might not be optimal, RECPAM analysis identiﬁed 4 subgroups of
patients with signiﬁcant differences in the prevalence of non-
adherence based on the interactions of work status, education level,
and marital status. We observed the higher risk of nonadherence
among nonretired, unmarried women. Being unmarried has been
previously reported as a predictor of poor adherence to medical
regimens in general43 and oral hormone therapy in particular.9,24
This highlights the important role of social support, mainly from
spouse and family members, as a factor for improving adherence.
The other factor affecting adherence was the level of education, with
patients with secondary or higher education showing a higher
prevalence of nonadherers. Highly educated patients are expected to
be more adherent because they should have a better knowledge of
the disease and possess the cultural tools required to independently
evaluate the beneﬁts of therapy. However, an inverse association
between educational level and adherence to treatment has been
reported in other diseases.44 This might reﬂect a more cynical belief
of educated patients regarding the usefulness of taking adjuvant
therapy and a lower level of trust in oncologists’ advice. The ﬁnal
logistic model with RECPAM classes forced-in conﬁrmed that
switching from tamoxifen to aromatase inhibitors represented an
important factor affecting adherence to this class of drugs.
Conclusion
Poor adherence to adjuvant endocrine treatment for breast cancer
is a well known problem and it is expected to become a more
compelling one in the coming years. Even if causes of nonadherence
were not speciﬁcally evaluated, results of our study help to deﬁne
discrete subgroups of “real life” patients with a high prevalence of
nonadherence and, to the best of our knowledge, represents the ﬁrst
Italian study of this kind in its speciﬁc setting. Therefore, our results
might be functional in designing intervention studies, speciﬁcally
targeting the high-risk patients with the aim of improving their
adherence. Likely these studies should be based on comprehensive
Nicola Tinari et alinterventions combining behavioral, educational, and affective
components.45
Clinical Practice Points
 Nonadherence to adjuvant endocrine treatment for breast cancer
is a well known problem, and it might explain the difference in
survival between clinical trial and clinical practice.
 Interventions aimed at promoting adherence have been proven to
be ineffective, probably because they were quite generic and not
adapted to the needs of the patient.
 We conducted a survey among women on adjuvant HT for
breast cancer with the aim to identify discrete subgroups at
higher prevalence of nonadherence.
 The results of our study indicate that women being unmarried,
employed, or a housewife are at higher risk of nonadherence.
 These ﬁndings might be instrumental in designing intervention
studies speciﬁcally targeting these high-risk patients with the aim
of improving their adherence.Acknowledgments
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